NRx Pharmaceuticals Forecasts $7.53M Q4 Revenue, $0.09 EPS Loss
NRx Pharmaceuticals projects a Q4 2025 loss per share of $0.09 on $7.53 million revenue and will host a March 24 conference call for full‐year results and drug development updates. Its valuation metrics remain extreme, with a price-to-sales ratio near 137, EV/Sales around 261 and a 0.29 current ratio.
1. Earnings Forecast and Conference Call
NRx Pharmaceuticals will report its Q4 2025 results around mid-to-late March, with analysts expecting a loss per share of $0.09. The company has scheduled a conference call on March 24 at 8:00 AM ET to discuss full-year 2025 financial results, drug development progress and the HOPE Therapeutics clinical network.
2. Revenue Projection and Development Update
Analysts forecast $7.53 million in Q4 2025 revenue, underscoring the pre-commercial stage of the firm’s pipeline. The upcoming call is expected to cover clinical milestones and next steps for depression, PTSD and suicide prevention therapies under development.
3. Valuation Metrics and Financial Health
Despite minimal traditional debt, the company’s price-to-sales ratio stands near 135–138 and EV/Sales around 258–264, while EV/OCF remains negative. A current ratio of 0.29 and negative book value per share of approximately -$0.93 highlight significant liquidity and capital structure challenges without additional funding.